NIRMATRELVIR/RITONAVIR

Course overview

NIRMATRELVIR/RITONAVIR ALSO REFERRED TO AS RITONAVIR-BOOSTED NIRMATRELVIR, IS AN ORAL COMBINATION MEDICATION USED TO TREAT CORONAVIRUS DISEASE 2019 (COVID-19). IT CONSISTS OF NIRMATRELVIR, A PROTEASE INHIBITOR TARGETING THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) MAIN PROTEASE, AND RITONAVIR, A CYTOCHROME P450 (CYP) 3A INHIBITOR. NIRMATRELVIR/RITONAVIR WAS AUTHORIZED FOR EMERGENCY USE ON DECEMBER 22, 2021. IT IS CURRENTLY ONE OF THE HIGHLY-EFFECTIVE ORAL ANTIVIRAL MEDICATIONS AVAILABLE TO TREAT COVID-19. THIS ACTIVITY REVIEWS THE MEDICATION’S INDICATIONS AND CONTRAINDICATIONS. IT ALSO REVIEWS THE MECHANISM OF ACTION, ADMINISTRATION, MONITORING, ADVERSE EFFECTS, TOXICITY, AND OTHER ELEMENTS RELATED TO TREATING PATIENTS WITH COVID-19. INFORMATION IN THIS ACTIVITY IS PERTINENT TO ALL MEMBERS OF THE INTERPROFESSIONAL HEALTHCARE TEAM, INCLUDING PHYSICIANS, PHARMACISTS, NURSES, AND OTHER HEALTH PROFESSIONALS, WHO MANAGE THE CARE OF PATIENTS WITH COVID-19.